These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 26694454)
21. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256 [TBL] [Abstract][Full Text] [Related]
22. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555 [TBL] [Abstract][Full Text] [Related]
23. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations. Sølund C; Krarup H; Ramirez S; Thielsen P; Røge BT; Lunding S; Barfod TS; Madsen LG; Tarp B; Christensen PB; Gerstoft J; Laursen AL; Bukh J; Weis N; PLoS One; 2014; 9(12):e113034. PubMed ID: 25438153 [TBL] [Abstract][Full Text] [Related]
25. A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection. Zoulim F; Moreno C; Lee SS; Buggisch P; Horban A; Lawitz E; Corbett C; Lenz O; Fevery B; Verbinnen T; Shukla U; Jessner W Virol J; 2018 Jan; 15(1):26. PubMed ID: 29378602 [TBL] [Abstract][Full Text] [Related]
26. Profile of alisporivir and its potential in the treatment of hepatitis C. Gallay PA; Lin K Drug Des Devel Ther; 2013; 7():105-15. PubMed ID: 23440335 [TBL] [Abstract][Full Text] [Related]
27. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents]. Li Z; Chen ZW; Ren H; Hu P Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402 [TBL] [Abstract][Full Text] [Related]
29. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden. Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241 [TBL] [Abstract][Full Text] [Related]
30. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection. Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551 [TBL] [Abstract][Full Text] [Related]
31. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance. Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498 [TBL] [Abstract][Full Text] [Related]
32. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir. Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808 [TBL] [Abstract][Full Text] [Related]
34. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents. Kalaghatgi P; Sikorski AM; Knops E; Rupp D; Sierra S; Heger E; Neumann-Fraune M; Beggel B; Walker A; Timm J; Walter H; Obermeier M; Kaiser R; Bartenschlager R; Lengauer T PLoS One; 2016; 11(5):e0155869. PubMed ID: 27196673 [TBL] [Abstract][Full Text] [Related]
36. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy. Wyles DL; Gutierrez JA J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691 [TBL] [Abstract][Full Text] [Related]
37. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Shah N; Pierce T; Kowdley KV Expert Opin Investig Drugs; 2013 Sep; 22(9):1107-21. PubMed ID: 23735127 [TBL] [Abstract][Full Text] [Related]
38. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment. Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342 [TBL] [Abstract][Full Text] [Related]
40. Comparison of Naturally Occurring Resistance-Associated Substitutions Between 2008 and 2016 in Chinese Patients with Chronic Hepatitis C Virus Infection. Huang W; Wang M; Gong Q; Yu D; Chen P; Lin J; Han Y; Su Y; Qu L; Zhang X Microb Drug Resist; 2019; 25(6):944-950. PubMed ID: 30702389 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]